Skip to main content

Advertisement

SpringerLink
Log in

The health-related quality of life of lung cancer patients with EGFR-TKI-related skin adverse drug reactions and its relationship with coping style and self-management

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The status and associated factors of the health-related quality of life of non-small-cell lung cancer (NSCLC) patients under targeted anti-cancer therapy have not been investigated. Self-management and coping style have been proven to be closely related to patients’ health-related quality of life. Based on these observations, this study was designed to firstly assess the status of health-related quality of life, and then explore the relationships among coping styles, self-management, and health-related quality of life of NSCLC patients with skin adverse drug reactions under targeted therapy.

Methods

We performed a cross-sectional study including 536 NSCLC patients with skin adverse drug reactions under targeted therapy in cancer clinics of three hospitals in China between May 2020 and May 2021. Structured questionnaires, including the Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18, Cancer Patient Self-management Evaluation Scale, and Medical Coping Modes Questionnaire, were used to collect data. Relationships among coping style, self-management, and health-related quality of life were identified by Pearson correlation analysis and a multiple linear regression algorithm.

Results

The total score of health-related quality of life was 46 ± 12.84 in 536 NSCLC patients with skin adverse drug reactions undergoing targeted therapy. Health-related quality of life was positively correlated with self-management (r = 0.785, P < 0.01) and facing (r = 0.807, P < 0.01) and negatively correlated with yield (r =  − 0.718, P < 0.01), avoidance (r =  − 0.711, P < 0.01), and the severity of skin adverse reactions (r =  − 0.722, P = 0.000). Via multiple linear regression analysis, we identified some significant factors associated with health-related quality of life, including age, education level, combination of medicine, Charlson Comorbidity Index, stages of disease, facing, yield, symptom management, daily activity management, psychological and emotional management, self-efficacy, and self-management (P < 0.05).

Conclusions

NSCLC patients with skin adverse drug reactions undergoing targeted therapy generally had a compromised health-related quality of life. The critical factors that were associated with the status of health-related quality of life were age, education level, comorbidity, the combinatorial application of drugs, stage of disease, self-management, and coping styles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The data generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author who was an organizer of the study.

Code availability

Not applicable.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) CA Cancer J Clin 71(3):209–249

    Article  PubMed  Google Scholar 

  2. Rongshou Z, Siwei Z, Hongmei Z, Changfa X (2022) J National Cancer Cent 12(3):525–537

    Google Scholar 

  3. Galvez-Nino M, Ruiz R, Pinto JA, Roque K, Mas L (2020) Lung Cancer 198(1):195–200

    Google Scholar 

  4. Thomas A, Chen Y, Yu T, Jakopovic M (2015) Front Oncol 5(33):113–119

    PubMed  PubMed Central  Google Scholar 

  5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Int J Cancer 136(5):E359–E386

    Article  CAS  PubMed  Google Scholar 

  6. Liu X, Luo X, Jiang C, Zhao H (2019) Clin Genet 95(6):569–574

    Article  PubMed  Google Scholar 

  7. Wilkes GM (2018) Asia Pac J Oncol Nurs 5(2):137–155

    Article  PubMed  PubMed Central  Google Scholar 

  8. Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM (2019) JAMA J Am Med Assoc 321(14):1391–1402

    Article  CAS  Google Scholar 

  9. Staats H, Cassidy C, Kelso J, Mack S, Nemunaitis J (2020) Biomedicine 5(13):27–49

    Google Scholar 

  10. Wu Y, Zhou C, Lu S, Qin S (2019) Lung Cancer 130(20):18–24

    Article  PubMed  Google Scholar 

  11. Ettinger DS, Wood DE, Akerley W, Bazhenova LA (2016) J Natl Compr Canc Netw Jnccn 14(3):255–264

    Article  PubMed  Google Scholar 

  12. Wang MC, Wang CL, Chen TL, Chang WC, Lu JJ, Chang PY, Chiou CC (2017) Clin Chem Lab Med 55(12):1979–1986

    Article  CAS  PubMed  Google Scholar 

  13. Kale HP, Mays AP, Nadpara PA, Slattum PW (2019) Urol Oncol 356(37):19–28

  14. Peng Y, Li Q, Zhang J, Shen W, Zhang X, Sun C, Cui H (2018) Biosci Trends 33(32):3817–3825

    Google Scholar 

  15. JLee JL, Jeong Y (2019) Cancer Nurs 42(6):475–483

  16. Barrios DM, Phillips GS, Freites-Martinez A, Hsu M, Lacouture ME (2019) J Eur Acad Dermatol 34(6):27–39

    Google Scholar 

  17. Chan JC, Lee YH, Liu CY, Shih HH, Tang WR (2019) J Nurs Res 27(6):51–59

    Article  Google Scholar 

  18. Yagasaki K, Komatsu H, Soejima K, Naoki K, Hamamoto Y (2018) Asia Pac J Oncol Nurs 5(2):172–177

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sano K, Nakadate K, Hanada K (2020) BMC Cancer 20(1):279–287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Komatsu H, Yagasaki K, Yamaguchi T, Mori A, Tamura K (2020) Eur J Oncol Nurs 23(8):1017–1028

    Google Scholar 

  21. Wagner LI, Lacouture ME (2007) Oncology 21(5):34–36

    PubMed  Google Scholar 

  22. Wagner LI, Berg SR, Gandhi M, Hlubocky FJ (2013) Support Care Cancer 21(4):1033–1041

    Article  PubMed  Google Scholar 

  23. Liao Y-C, Liao W-Y, Sun J-L, Ko J-C, Yu C-J (2018) Support Care Cancer 26(2):989–996

    Article  PubMed  Google Scholar 

  24. Yuan M, Huang LL, Chen JH, Wu J, Xu Q (2019) Signal Transduct Target Ther 55(5):103–111

    Google Scholar 

  25. Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A (2016) Cancer Nurs 39(6):437–445

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E (2018) Clin Colorectal Canc 17(2):85–96

    Article  Google Scholar 

  27. Huang FF, Yang Q, Zhang J, Han XY, Zhang JP, Chirico A (2018) PLoS ONE 13(9):332–339

    Google Scholar 

  28. Chirico A, Lucidi F, Merluzzi T, Alivernini F, Giordano A (2017) Oncotarget 8(22):36800–36811

    Article  PubMed  PubMed Central  Google Scholar 

  29. Chen H, Senan S, Nossent EJ, Boldt RG, Warner A, Palma DA, Louie AV (2017) Int J Radiat Oncol 47(6):327–336

    Google Scholar 

  30. Charan J, Biswas T (2013) Indian J Psychol Med 35(2):121–126

    Article  PubMed  PubMed Central  Google Scholar 

  31. Qing L, Yanmei P, Jingyi Z, Shen W (2020) J China-Japan Friendship Hospital 34(5):263–267

  32. Lingling C (2017) S Yuqian. Chin J Nurs 52(9):1082–1087

    Google Scholar 

  33. Sun V, Reb A, Debay M, Fakih M, Ferrell B (2021) J Cancer Educ 36(4):421–428

    Article  PubMed  PubMed Central  Google Scholar 

  34. Xiaohong S, Qianjin J (2000) Chin J Behav Med Brain Sci 9(1):18–20

    Google Scholar 

  35. Wu XD, Qin HY, Zhang JE, Zheng MC, Xin MZ, Liu L, Wu XJ, Jiang CN, Zhang MF (2015) Eur J Oncol Nurs 21(5):725–732

    Google Scholar 

  36. He Y, Jian H, Yan M, Zhu J, Chen J (2019) BMJ Open 9(5):233–239

    Google Scholar 

  37. Hauke J, Kossowski T (2011) Quaest Geogr 30(2):87–93

    Article  Google Scholar 

  38. Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, Ocana A (2017) Cancer Treat Rev 56(6):1–7

    Article  CAS  PubMed  Google Scholar 

  39. Yamamoto K, Yano I (2018) Med Oncol 35(2):16–26

    Article  PubMed  Google Scholar 

  40. Du R, Wang X, Ma L, Larcher LM, Wang T (2021) BMC Cancer 21(1):231–239

    Article  Google Scholar 

  41. Occhipinti M, Brambilla M, Galli G, Manglaviti S, Prelaj A, Ferrara R, Toma AD, Beninato T, Zattarin E, Proto C (2021) J Thorac Oncol 16(4):1257–1265

    Article  Google Scholar 

  42. Chen CB, Wu MY, Yee NC, Lu CW, Wu J, Pei-Han K, Yang CK, Peng MT, Huang CY, Chang WC (2018) Cancer Manag Res 10:1259–1273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Deutsch A, Leboeuf NR, Lacouture ME, Mclellan BN (2020) Proc Am Soc Clin Oncol 40(40):485–500

    Google Scholar 

  44. He Y, Jian H, Yan M, Zhu J, Chen J (2019) BMJ Open 9(5):236–242

    Google Scholar 

  45. Cheng T, Respiration DO (2016) China Health Industry 13(16):532–536

    Google Scholar 

  46. De W, Derijcke S, Galdermans D, Daenen M, Surmont V, Droogh ED, Lefebure A, Saenen E, Vandenbroucke E, Morel AM (2020) Clin Lung Cancer 2(22):146–152

    Google Scholar 

  47. Kafatos G, Dube S, Burdon P, Demonty G, Flinois A, Leclerc M, Lowe K, Feudjo-Tepie M, Segaert S (2020) Clin Colorectal Canc 19(2):100–108

    Article  Google Scholar 

  48. Sun V, Reb A, Debay M, Fakih M, Ferrell B (2021) J Cancer Educ 25(4):788–796

    Google Scholar 

  49. Chen Q, Di S, Ying Y, Yue Z, Xiaoying Z (2019) Qual Life Res Int J Qual Life Asp Treat Care Rehabil 67(5):1245–1253

    Google Scholar 

  50. Liao Y-C, Liao W-Y, Sun J-L, Ko J-C, Yu C-J (2018) Support Care Cancer 12(23):236–243

    Google Scholar 

  51. Huang W, Li J, Qiu F, Wu X, Zhu S (2020) J Clin Pharm Ther 45(12):29–39

    Google Scholar 

Download references

Acknowledgements

We thank the First Affiliated Hospital of Zhengzhou University and Henan Tumor Hospital and the First Affiliated Hospital of Henan University of Science and Technology for their assistance and support and the Follow-up Registration System and data provided by the Follow-up Center of the First Affiliated Hospital of Zhengzhou University. We also thank the oncologists and nurses of the three hospitals. We appreciate all participants for their generous participation.

Funding

This study received financial support from the China Postdoctoral Science Foundation in 2018 (2018M630839) and the National Natural Science Foundation of China (no. 81773175)

Author information

Authors and Affiliations

  1. The College of Nursing and Health of Zhengzhou University, Zhengzhou, 450001, China

    Ruofei Du, Xin Wang, Huiyue Zhou & Tao Wang

  2. The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China

    Ruofei Du & Changying Chen

  3. School of Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China

    Ruofei Du

  4. School of Statistics, Henan University of Economics and Law, Zhengzhou, 450046, China

    Lixia Ma

  5. Centre for Comparative Genomics, Murdoch University, Perth, WA, 6150, Australia

    Leon M. Larcher

  6. Telethon Kids Institute, Perth, WA, 6872, Australia

    Tao Wang

  7. School of Medicine, University of Western Australia, Perth, WA, 6872, Australia

    Tao Wang

  8. Hebi People’s Hospital, Hebi, 458030, China

    Tao Wang

Authors
  1. Ruofei Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huiyue Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lixia Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leon M. Larcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Changying Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have read and approved the manuscript. WT and CCY were responsible for the overall design and quality control of the study as well as the communication with the hospital and departments reviewed. DRF, WX, and WT made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; WX, LML, and MLX were involved in drafting the manuscript or revising it critically for important intellectual content; ZHY contributed to the training and management of nurses and students who collected data. DRF, ZHY, WX, LML, CCY, and WT gave final approval of the version to be published. MLX contributed to data analysis and solving statistical problems. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; DRF, CCY, and WT agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding authors

Correspondence to Changying Chen or Tao Wang.

Ethics declarations

Ethics approval

This study was approved by the Ethics Committee of our university and administrative permissions were obtained from directors of oncology departments. All methods were carried out in accordance with relevant guidelines and regulations. Information about the study was provided to the participants, and we obtained written informed consent from all participants prior to their inclusion in the study.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, R., Wang, X., Zhou, H. et al. The health-related quality of life of lung cancer patients with EGFR-TKI-related skin adverse drug reactions and its relationship with coping style and self-management. Support Care Cancer 30, 9889–9899 (2022). https://doi.org/10.1007/s00520-022-07451-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-022-07451-2

Keywords

Search

Navigation